Email ID
Password
Scrip   
Dynavax exercises Symphony option for cash to fund Heplisav
11 November 2009
Sukaina Virji

Dynavax Technologies is exercising its option to purchase Symphony Dynamo (SDI), reaping $20 million in cash and rights to hepatitis C and cancer therapy programmes that were licensed from Dynavax.

SDI was set up in 2006 with Symphony Capital, a private equity fund, providing $50 million...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36